Oxnard on Opening the Door for Precision Medicine in Lung Cancer
In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Geoffrey R. Oxnard, MD, vice president, global medical lead, liquid franchise, at Foundation Medicine, to discuss the current state of treatment in lung cancer and the potential reach of liquid biopsy in the field.
In our exclusive interview, Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
